Dawn Biopharma
VC Fund
Wilmington, United States
Dawn Biopharma is a global investment firm of KKR.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Dawn Biopharma invests in
Stages Dawn Biopharma invests in
Countries Dawn Biopharma invests in
Round sizes
Round size
- Seed
- $15M–$32M
- Series A
- $17M–$165M
- Series B
- $115M–$135M
Investment Focus
Industry
- Biotechnology 8 (57%)
- Health Care 4 (29%)
- Therapeutics 3 (21%)
- Medical 2 (14%)
- Oncology 1 (7%)
Stage
- Series A 6 (43%)
- Seed 2 (14%)
- Series B 2 (14%)
- Series C 2 (14%)
- Post-IPO Equity 1 (7%)
Country
- United States 3 (21%)
- Denmark 2 (14%)
- France 1 (7%)
- Belgium 1 (7%)
- Germany 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Expedition Therapeutics
|
Expedition Therapeutics operates as an unincorporated association. | $115M / Series B / Aug 05, 2026 | |
Vedana Therapeutics
|
Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention. | $46M / Series A / Jun 17, 2026 | |
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M / Series C / Apr 14, 2026 | |
Bambusa Therapeutics
|
Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies. | Series A / Nov 17, 2025 | |
Adcytherix
|
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M / Series A / Oct 16, 2025 | |
|
Expedition Therapeutics
|
Expedition Therapeutics operates as an unincorporated association. | $165M / Series A / Oct 09, 2025 | |
Antag Therapeutics
|
Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner. | $84.1M / Series A / Dec 04, 2024 | |
|
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $135M / Series B / Nov 25, 2024 | |
|
Bambusa Therapeutics
|
Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies. | $15M / Seed / Sep 09, 2024 | |
|
Adcytherix
|
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $32.2M / Seed / Jun 11, 2024 | |
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Dawn Biopharma invest in?
Dawn Biopharma invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Dawn Biopharma's check size?
Dawn Biopharma typically joins rounds of $15M–$32M at Seed, $17M–$165M at Series A and $115M–$135M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Dawn Biopharma participates in.
When did Dawn Biopharma last invest?
The most recent investment recorded for Dawn Biopharma closed in Aug 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
